Treatment of Locally Advanced Esophageal Carcinoma: ASCO Guideline

Shah, Manish A.; Kennedy, Erin B.; Catenacci, Daniel V.T.; Deighton, Dana; Goodman, Karyn A.; Malhotra, Narinder K.; Willett, Christopher G.; Stiles, Brendon M.; Sharma, Prateek; Tang, Laura H.; Wijnhoven, Bas P. L.; Hofstetter, Wayne L.

doi:10.1200/jco.20.00866

Cited by 216 publications

(175 citation statements)

References 62 publications

Supporting

Mentioning

164

Contrasting

Unclassified

Order By: Relevance

“…Chemotherapy is also widely used preoperatively in a number of centres, with improved survival over unimodality surgery 14 . Neoadjuvant therapy (either chemotherapy or chemoradiotherapy) is therefore recommended for all fit patients with locally advanced disease in current guidelines 15 . Survival in operatively managed patients is relatively favourable, at around 35–45% at 5 years 12,16 .…”

Section: Treatment Strategiesmentioning

confidence: 99%

Oestrogen receptors: A potential therapeutic target in oesophageal adenocarcinoma?

Due

Watson

Hussey

2021

ANZ Journal of Surgery

View full text Add to dashboard Cite

Oesophageal cancer is the seventh most common cancer in the world and adenocarcinoma is the dominant subtype in Western industrialised nations. The global 5‐year relative survival rate for oesophageal adenocarcinoma is 12%. Chemotherapy is a standard treatment offered to patients with both resectable and unresectable disease. However, there are only a few established chemotherapeutic drug options and progress in this area is limited. Recent efforts have focused on targeted molecular therapies. Epidemiological evidence points towards hormonal influences on disease development, particularly sex hormones. Several research studies have demonstrated oestrogen receptor (ER) expression in oesophageal adenocarcinoma tissue, making them a possible option for targeting with ER modulating agents. ERs are also present in laboratory models of the disease and experiments in ER‐positive cell lines suggest that ER modulator therapy may be effective. A deeper understanding of the roles of ERα and ERβ in this disease would be valuable for future translation into clinical practice. In this review, we discuss the association between oestrogens and the development of oesophageal adenocarcinoma and the potential to modulate ER signalling networks for therapeutic benefit.

show abstract

Section: Treatment Strategiesmentioning

confidence: 99%

Oestrogen receptors: A potential therapeutic target in oesophageal adenocarcinoma?

Due

Watson

Hussey

2021

ANZ Journal of Surgery

View full text Add to dashboard Cite

show abstract

“…As the sixth leading cause of cancer deaths worldwide, esophageal cancer (EC) is a lethal disease with an unsatisfactory prognosis 1 . Concurrent chemoradiotherapy (CRT) is the standard of care for patients with EC unsuitable for surgery 2 . Despite therapeutic advances in radiotherapy modality and chemotherapy regimens in recent years, the prognosis for patients who receive definitive CRT remains unfavorable, with 3-year overall survival (OS) rates of 26.9–55.4% 3 – 8 .…”

Section: Introductionmentioning

confidence: 99%

Induction chemotherapy followed by definitive chemoradiotherapy versus chemoradiotherapy alone in esophageal squamous cell carcinoma: a randomized phase II trial

et al. 2021

View full text Add to dashboard Cite

This randomized phase II trial aims to compare the efficacy and safety of induction chemotherapy followed by definitive chemoradiotherapy (CRT) versus CRT alone in patients with esophageal squamous cell carcinoma (ESCC) unsuitable for surgery (N = 110). The primary outcome was overall response rate (ORR), whereas the secondary outcome was overall survival. This trial did not meet pre-specified endpoints. The ORR was 74.5% in the induction chemotherapy group versus 61.8% in the CRT alone group (P = 0.152). The 3-year overall survival rate was 41.8% in the induction chemotherapy group and 38.1% in the CRT alone group (P = 0.584; hazard ratio, 0.88; 95% CI, 0.54–1.41). Grade 3–5 adverse events were similar. Patients who responded to induction chemotherapy had improved survival in the post-hoc analysis. These results demonstrate no improvement in response rate or survival with the addition of induction chemotherapy to CRT in unselected patients with ESCC. Trial number: NCT02403531.

show abstract

“…Most patients with EC were discovered in advanced stages, and had adverse therapeutic effect. The common treatments were chemotherapy, chemoradiotherapy and surgical resection [15,16] . Reflux disease is associated with an increased risk of esophagitis, esophageal strictures, Barrett esophagus, and esophageal adenocarcinoma, and it has the similar symptoms to EC [17,18] .…”

Section: Discussionmentioning

confidence: 99%

Study on the Value of C1q in the Diagnosis of Esophageal Cancer

Cai¹,

Li²,

Chen³

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Esophageal cancer was hardly diagnosed in early stage, and more potential biomarkers should be found. Methods: 252 patients and normal controls which recruited in Renmin Hospital of Wuhan University, were divided into esophageal carcinoma group (105 cases), disease control group (75 cases) and the control group of healthy people (72 cases). Moreover, TISIDB and GEPIA databases were used to investigate the different expression of EC and normal tissues, and explore the roles of C1q in tumor-immune system interactions in EC. Results: The concentration of serum C1q in EC group is 196.8(180~219.4) mg/L, which is higher than the level of DC [178.10(153.70~200.85) mg/L]and HC [183.00(167.75~201.00) mg/L] (P<0.05). A higher expression level of C1q was observed in Ⅲ and Ⅳ grades [214(192~237.3) mg/ml] than grades Ⅰ and Ⅱ [180.95(172.03~193.85) mg/L] (P<0.05). C1q was positively correlated with eosinophils, active CD8 T cells, myeloid derived suppressor cells, natural killer cells, monocytes and macrophages (r = 0.373; r = 0.659; r = 0.846; r = 0.760; r = 0.499; r = 0.757; P<0.05). Conclusion: The concentrations of C1q increased in EC and related to the severity of EC, which had potential value of diagnosis of EC. There were correlations in C1q and tumor-infiltrating lymphocytes.

show abstract

Treatment of Locally Advanced Esophageal Carcinoma: ASCO Guideline

Cited by 216 publications

References 62 publications

Oestrogen receptors: A potential therapeutic target in oesophageal adenocarcinoma?

Oestrogen receptors: A potential therapeutic target in oesophageal adenocarcinoma?

Induction chemotherapy followed by definitive chemoradiotherapy versus chemoradiotherapy alone in esophageal squamous cell carcinoma: a randomized phase II trial

Study on the Value of C1q in the Diagnosis of Esophageal Cancer

Contact Info

Product

Resources

About